Please assess the completion status of the following clinical trial:

Trial Title: Persantine: Variation in Response Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients \> 21 years old~* Patient undergoing cardiac catheterization with planned PTCA or with a significant coronary lesion of either the LAD or Circumflex~Exclusion Criteria:~* Theophylline or oral Persantine use in 24hrs~* Second or third degree AV block, or sick sinus syndrome without a functioning pacemaker~* Active asthma or bronchospasm~* Patients with severe hepatic insufficiency~* Patients experiencing an acute transmural infarction at the time of the index visit~* Conditions that are known to affect resistive vessel function or myocardial flow

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All subjects receive dipyridamole (Type: OTHER): Compare to baseline

Based on this trial design, predict the completion outcome and termination type (if applicable).